VFH vs XBI
Vanguard Financials ETF vs SPDR S&P Biotech ETF
- • VFH has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VFH pays a higher dividend yield (1.71%).
Side-by-side metrics
| Metric | VFH | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.71% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $14.54B | $10.92B |
YTD return | 6.78% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.76 | 1.01 |
P/E ratio | 15.99 | — |
Last price | $141.53 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VFH top holdings
| JPM | JPMorgan Chase & Co | 10.42% |
| BRK-B | Berkshire Hathaway Inc Class B | 8.32% |
| V | Visa Inc Class A | 7.07% |
| MA | Mastercard Inc Class A | 5.30% |
| BAC | Bank of America Corp | 4.19% |
| GS | The Goldman Sachs Group Inc | 2.94% |
| WFC | Wells Fargo & Co | 2.87% |
| MS | Morgan Stanley | 2.63% |
| C | Citigroup Inc | 2.60% |
| SCHW | Charles Schwab Corp | 1.91% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VFH
VFH (Vanguard Financials ETF) is US financial services sector stocks. Managed by Vanguard, the fund carries $14.5B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.71%. Its largest holding is JPMorgan Chase & Co (JPM), which represents 10.4% of the portfolio. Real Estate is the fund's largest sector exposure at 0.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.